<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twice-weekly <z:chebi fb="0" ids="52717">bortezomib</z:chebi> has proven activity in mantle cell (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) and indolent <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This study explored a weekly schedule of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Although weekly <z:chebi fb="0" ids="52717">bortezomib</z:chebi> was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0.02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule) </plain></SENT>
<SENT sid="3" pm="."><plain>Progression-free survival (PFS) was not different </plain></SENT>
<SENT sid="4" pm="."><plain>The weekly schedule of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> was less toxic, but yielded fewer and lower quality responses than twice-weekly <z:chebi fb="0" ids="52717">bortezomib</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Given the similar PFS, the weekly schedule may still be appropriate for some patients </plain></SENT>
</text></document>